PDE5A and pulmonary arterial hypertension: So far, therapeutic strategies for treating PAH are mainly focused on improving pulmonary vasculature vasodilation mediated by the NO pathway; endothelin, prostaglandin, thromboxane receptors; and PDE5 inhibitors, and more than one drug is needed to correct them [54].